A Phase 3 interventional study of Placebo and Ravulizumab in Amyotrophic Lateral Sclerosis and ALS, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 95 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 21st largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 30 in phase 3, and was the 256th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 382 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ravulizumab for the duration of the study.
Biological: Ravulizumab
Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
Drug: Placebo · Biological: Ravulizumab
Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Also known as: ALXN1210, Ultomiris
Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score
The ALSFRS-Revised is a validated instrument for evaluating the levels of the functional status of participants with amyotrophic lateral sclerosis (ALS) in 4 areas, including bulbar, gross motor activity, fine motor activity, and respiratory functions. The scale included 12 functional items and each item is rated on a 0 to 4 scale, with a maximum total score of 48. A higher score indicated greater retention of function. Baseline was defined as last non-missing value on or before first study drug administration.
Time frame: Baseline, Week 50
Time To Ventilator Assistance-free Survival
Ventilation Assistance-Free Survival (VAFS) is a composite endpoint of survival and severe and irreversible respiratory decline. The use of VAFS allowed for the collection of survival data that was not impacted by survival prolongation from noninvasive or permanent ventilatory interventions which could prolong life without impacting underlying disease progression.
Time frame: Up to Week 50
Change From Baseline In Percent Predicted Slow Vital Capacity
Slow vital capacity measures slow and gradual expulsion of air from the lungs using a spirometer.
Time frame: Baseline, Week 50
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, and TEAEs Leading To Study Drug Discontinuation
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline up to Week 156
Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry
Handheld dynamometry (HHD) is a procedure for quantitative strength testing. Muscle strength testing was performed on prespecified muscles in the upper and lower extremities bilaterally and the force measurements were recorded. Force of measurement is reported in megascores (lower, upper, total). The total megascore is defined as the average of the non-missing ratios over baseline for all the muscles involved. The megascore at baseline is always 100. The range of a potential megascore can not be determined in advance. A megascore \>100 indicates more strength compared to baseline.
Time frame: Baseline, Week 50
Change From Baseline In Serum Neurofilament Light Chain
Time frame: Baseline, Week 50
Change From Baseline in Serum Ravulizumab Concentration Over the Study Duration
Time frame: Baseline, Predose at Week 50
Change From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration
Time frame: Baseline, Predose at Week 50
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Blood samples were collected to evaluate antibody response through development of ADAs.
Time frame: Week 50
| Milestone | Ravulizumab/Ravulizumab | Placebo/Ravulizumab |
|---|---|---|
| Started | 255 | 127 |
| Received at least 1 dose of study drug | 255 | 127 |
| Completed | 15 | 5 |
| Not completed | 240 | 122 |
| Withdrew: Death | 12 | 5 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Study terminated by sponsor | 194 | 99 |
| Withdrew: Withdrawal by subject | 30 | 17 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Ravulizumab/Ravulizumab | Placebo/Ravulizumab |
|---|---|---|
| Started | 14 | 5 |
| Received at least 1 dose of study drug | 14 | 5 |
| Completed | 0 | 0 |
| Not completed | 14 | 5 |
| Withdrew: Study terminated by sponsor | 14 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The ALSFRS-Revised is a validated instrument for evaluating the levels of the functional status of participants with amyotrophic lateral sclerosis (ALS) in 4 areas, including bulbar, gross motor activity, fine motor activity, and respiratory functions. The scale included 12 functional items and each item is rated on a 0 to 4 scale, with a maximum total score of 48. A higher score indicated greater retention of function. Baseline was defined as last non-missing value on or before first study drug administration.
| units on a scale | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score | -11.9 ± 7.30 | -10.6 ± 6.05 |
Ventilation Assistance-Free Survival (VAFS) is a composite endpoint of survival and severe and irreversible respiratory decline. The use of VAFS allowed for the collection of survival data that was not impacted by survival prolongation from noninvasive or permanent ventilatory interventions which could prolong life without impacting underlying disease progression.
| months | Ravulizumab | Placebo |
|---|---|---|
| Time To Ventilator Assistance-free Survival | 6.05 (0.79 to 11.10) | 7.69 (4.83 to 9.53) |
Slow vital capacity measures slow and gradual expulsion of air from the lungs using a spirometer.
| percentage of predicted volume | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline In Percent Predicted Slow Vital Capacity | -20.9 ± 19.74 | -21.3 ± 13.90 |
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| TEAEs | 204 | 108 |
| Treatment Emergent Serious AEs | 41 | 24 |
| TEAE Leading to Study Drug Discontinuation | 2 | 0 |
Handheld dynamometry (HHD) is a procedure for quantitative strength testing. Muscle strength testing was performed on prespecified muscles in the upper and lower extremities bilaterally and the force measurements were recorded. Force of measurement is reported in megascores (lower, upper, total). The total megascore is defined as the average of the non-missing ratios over baseline for all the muscles involved. The megascore at baseline is always 100. The range of a potential megascore can not be determined in advance. A megascore \>100 indicates more strength compared to baseline.
| % (as the unit of megascore) | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry | -46.5 ± 27.57 | -53.4 ± 20.28 |
| picograms/milliliter | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline In Serum Neurofilament Light Chain | 91.5 ± 40.40 | 73.1 ± 27.82 |
| micrograms/milliliter | Ravulizumab |
|---|---|
| Change From Baseline in Serum Ravulizumab Concentration Over the Study Duration | 634 ± 29.1 |
| micrograms/milliliter | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration | -155.2 ± 24.42 | — |
Blood samples were collected to evaluate antibody response through development of ADAs.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210 | 0 | — |
Collected over Baseline up to Week 156. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Controlled Period: Ravulizumab | 15/255 (5.9%) | 41/255 (16.1%) | 196/255 (76.9%) |
| Randomized Controlled Period: Placebo | 6/127 (4.7%) | 24/127 (18.9%) | 106/127 (83.5%) |
| Open Label Extension Period: Ravulizumab | 0/14 (0%) | 2/14 (14.3%) | 3/14 (21.4%) |
| Open Label Extension Period: Placebo | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Randomized Controlled Period: Ravulizumab | Randomized Controlled Period: Placebo | Open Label Extension Period: Ravulizumab | Open Label Extension Period: Placebo |
|---|---|---|---|---|
| COVID-19Infections and infestations | 0/255 | 1/127 | 1/14 | 0/5 |
| CholecystitisHepatobiliary disorders | 0/255 | 0/127 | 1/14 | 0/5 |
| PneumoniaInfections and infestations | 3/255 | 5/127 | 0/14 | 0/5 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 8/255 | 4/127 | 0/14 | 0/5 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/255 | 4/127 | 0/14 | 0/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/255 | 2/127 | 0/14 | 0/5 |
| Pneumonia aspirationInfections and infestations | 2/255 | 2/127 | 0/14 | 0/5 |
| DysphagiaGastrointestinal disorders | 1/255 | 2/127 | 0/14 | 0/5 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/255 | 1/127 | 0/14 | 0/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/255 | 1/127 | 0/14 | 0/5 |
| Event | Randomized Controlled Period: Ravulizumab | Randomized Controlled Period: Placebo | Open Label Extension Period: Ravulizumab | Open Label Extension Period: Placebo |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 54/255 | 36/127 | 1/14 | 1/5 |
| HordeolumInfections and infestations | 0/255 | 0/127 | 0/14 | 1/5 |
| Ankle fractureInjury, poisoning and procedural complications | 0/255 | 0/127 | 0/14 | 1/5 |
| HeadacheNervous system disorders | 42/255 | 22/127 | 1/14 | 0/5 |
| ConstipationGastrointestinal disorders | 26/255 | 5/127 | 0/14 | 0/5 |
| NauseaGastrointestinal disorders | 23/255 | 10/127 | 0/14 | 0/5 |
| FatigueGeneral disorders | 22/255 | 11/127 | 0/14 | 0/5 |
| Urinary tract infectionInfections and infestations | 12/255 | 11/127 | 0/14 | 0/5 |
| Back PainMusculoskeletal and connective tissue disorders | 21/255 | 5/127 | 0/14 | 0/5 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/255 | 0/127 | 1/14 | 0/5 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug grouped by randomized treatment group.
| Age, Continuous(years) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Mean | 58.6 ± 10.57 | 58.0 ± 11.03 | 58.4 ± 10.72 |
| Sex: Female, Male(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Female | 94 | 58 | 152 |
| Male | 161 | 69 | 230 |
| Ethnicity (NIH/OMB)(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 12 | 34 |
| Not Hispanic or Latino | 205 | 105 | 310 |
| Unknown or Not Reported | 28 | 10 | 38 |
| Race (NIH/OMB)(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 22 | 12 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 202 | 103 | 305 |
| More than one race | 4 | 0 | 4 |
| Unknown or Not Reported | 26 | 10 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Oct 2021, 18 months.
Results were first posted in Jan 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Amyotrophic Lateral Sclerosis →
Alexion Pharmaceuticals, Inc. →